CD38 as a pan-hematologic target for chimeric antigen receptor T cells

Many hematologic malignancies are not curable with chemotherapy and require novel therapeutic approaches. Chimeric antigen receptor (CAR) T-cell therapy is 1 such approach that involves the transfer of T cells engineered to express CARs for a specific cell-surface antigen. CD38 is a validated tumor...

Descripción completa

Detalles Bibliográficos
Autores principales: Glisovic-Aplenc, Tina, Diorio, Caroline, Chukinas, John A., Veliz, Kimberly, Shestova, Olga, Shen, Feng, Nunez-Cruz, Selene, Vincent, Tiffaney L., Miao, Fei, Milone, Michael C., June, Carl H., Teachey, David T., Tasian, Sarah K., Aplenc, Richard, Gill, Saar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2023
Materias:
Immunobiology and Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10440474/
https://www.ncbi.nlm.nih.gov/pubmed/37171449
http://dx.doi.org/10.1182/bloodadvances.2022007059

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10440474/
https://www.ncbi.nlm.nih.gov/pubmed/37171449
http://dx.doi.org/10.1182/bloodadvances.2022007059

Ejemplares similares